Trupanion (TPW) AI Stock Analysis

Trupanion

(BX Swiss:TPW)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring subscription growthSubscription premiums provide recurring revenue, and continued growth in both revenue and enrolled pets indicates expanding customer adoption. This recurring base can support durable operating leverage as Trupanion scales policy administration and claims infrastructure.

Negative Factors

Thin profitability and margin pressureAlthough earnings have recovered, profitability remains narrow and the lower gross margin signals pressure on underlying economics. Small increases in claims or operating costs could therefore materially affect earnings, limiting the durability of the current recovery until margins rebuild.

Trupanion Business Overview & Revenue Model

Company Description

Trupanion, Inc. provides monthly subscription-based medical insurance for canine and feline companions across the United States, Canada, Puerto Rico, and Australia. The company's operations are divided into two main categories: Subscription Business...

Trupanion Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentPositive

The call highlighted strong top-line and operating income growth, improved unit economics (25% LTV increase), accelerating net pet adds and healthy free cash flow, alongside disciplined capital allocation actions including a $100M share repurchase program and dividends unlocked from insurance entities. Offsetting risks include persistent double-digit veterinary inflation that pressures member economics, a modest decline in the value-proposition metric, rising pet acquisition cost, a year-over-year decline in net income due in part to prior-year one-time items, and a planned partner termination with Pets Best. Overall, operational momentum and cash generation appear to outweigh the manageable industry and partner challenges.

Positive Updates

Revenue Growth

Total revenue of $392.9M in Q2, up 11% year-over-year; subscription revenue $276.7M, up 14% year-over-year.

Negative Updates

Veterinary Inflation and Industry Headwinds

Veterinary inflation remains at double-digit levels (though moderating), pressuring pricing and member economics and prompting higher-than-average pricing flows through the book; reported fewer wellness visits while veterinarians increased prices to maintain revenue.

Company Guidance

Trupanion narrowed its 2026 guidance, calling for full‑year total revenue of $1.584–$1.601 billion, subscription revenue of $1.124–$1.133 billion (midpoint ≈14% YoY), and total adjusted operating income of $176–$184 million (midpoint ≈19% YoY; management also said it remains on track for about $180 million AOI); for Q3 2026 the company expects total revenue of $399–$405 million, subscription revenue of $284–$287 million (≈13% YoY at the midpoint) and total AOI of $44–$47 million (≈11% YoY at the midpoint), with guidance prepared using a 71% USD/CAD conversion rate.

Trupanion Risk Analysis

Trupanion disclosed 56 risk factors in its most recent earnings report. Trupanion reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Trupanion Peers Comparison

Overall Rating

UnderperformOutperform

Sector (68)

Financial Indicators

CH:TPW against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGR	87Outperform	$134.40B	11.62	35.44%	6.01%	7.67%	8.87%
CB	84Outperform	$139.12B	12.65	15.06%	1.09%	5.89%	19.00%
ERIE	82Outperform	$12.17B	21.13	23.86%	2.24%	1.97%	-11.09%
AFG	77Outperform	$12.76B	13.44	20.01%	4.62%	-1.43%	25.53%
Sector *	68Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
LMND	66Neutral	$3.32B	-22.96	-26.78%	―	76.73%	35.36%

* Financial Sector Average

Performance Comparison

CH:TPW and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CB	Chubb Ltd	364.12	89.26	32.47%
AFG	American Financial	153.87	30.13	24.35%
ERIE	Erie Indemnity	261.39	-17.38	-6.24%
PGR	The Progressive Corporation	231.28	40.02	20.93%
LMND	Lemonade Inc	42.94	-18.60	-30.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Trupanion AI Stock Analysis